Processa Pharmaceuticals, Inc. (PCSA) - Dilution Analysis

10-Q filing | 2.6M shares outstanding

10-K filing | 2.7M shares outstanding

8-K filing: Stock split 1-for-25 | Outstanding: 56,644,223 → 2,265,768

10-Q filing | 56.6M shares outstanding

8-K filing: Processa Pharmaceuticals, Inc. entered into securities purchase agreements for a private placement, selling 5,467,181 restricted shares of common stock at $0.23 per share, resulting in gross proceeds of approximately $1.3 million, which closed on August 6, 2025. ($1.3M proceeds)

8-K filing: Processa Pharmaceuticals, Inc. filed a prospectus supplement permitting the Company to sell $5,239,073 shares of its common stock, with $1,546,338 shares already sold and $3,692,735 available for sale.

8-K filing: Processa Pharmaceuticals, Inc. sold 14,310,000 shares of common stock, Pre-Funded Warrants to purchase up to 13,690,000 shares of common stock, and Common Warrants to purchase up to 28,000,000 shares of common stock in a registered public offering, closing on June 18, 2025, with gross proceeds of approximately $6.3 million. ($6.3M proceeds)

S-1 filing: Processa Pharmaceuticals, Inc. is offering shares of common stock and warrants to purchase common stock for working capital purposes.

10-Q filing | 11.9M shares outstanding

10-K filing | 5.3M shares outstanding

8-K filing: Processa Pharmaceuticals, Inc. closed a registered direct offering on January 29, 2025, selling 1,030,972 shares of common stock, Series A Warrants to purchase up to 8,050,672 shares, Series B Warrants to Purchase up to 4,025,336 Shares, and Pre-Funded Warrants to purchase up to 7,019,700 shares for gross proceeds of approximately $5.0 million. ($5.0M proceeds)

S-1/A filing: Processa Pharmaceuticals, Inc. is offering up to 11,764,706 shares of common stock at an assumed public offering price of $0.68 per share, along with warrants to purchase additional common stock, with the net proceeds to be used to continue the Phase 2 clinical trial of NGC-Cap and for working capital and other general corporate purposes.

S-1/A filing: This S-1/A filing details an offering of up to 9,400,705 shares of common stock, pre-funded warrants, and common warrants with the net proceeds to be used to continue the Phase 2 clinical trial of NGC-Cap and for working capital and other general corporate purposes.

S-1 filing: This S-1 filing is for a proposed offering of common stock and pre-funded warrants.

10-Q filing | 3.3M shares outstanding

10-Q filing | 3.0M shares outstanding

S-3 filing: The company may offer and sell from time to time up to $50,000,000 of any combination of common stock and preferred stock.

10-Q filing | 2.9M shares outstanding

10-K filing | 2.9M shares outstanding

8-K filing: Processa Pharmaceuticals, Inc. closed a registered public offering on January 30, 2024, selling 476,000 shares of common stock, warrants to purchase 1,555,555 shares of common stock, and pre-funded warrants to purchase up to 1,079,555 shares of common stock, with gross proceeds of approximately $7.0 million. ($7.0M proceeds)

S-1/A filing: The filing is an S-1/A for a proposed offering of common stock and pre-funded warrants. The company intends to use the net proceeds from the offering to begin a Phase 2 clinical trial of NGC-Cap and for working capital and other general corporate purposes.

8-K filing: Stock split 1-for-20 | Outstanding: 24,631,474 → 1,231,573

S-1 filing: Processa Pharmaceuticals, Inc. is filing an S-1 form offering shares of common stock, pre-funded warrants, and common warrants.

10-Q filing | 27.0M shares outstanding

10-Q filing | 26.9M shares outstanding

10-Q filing | 22.8M shares outstanding

10-K filing | 24.6M shares outstanding

8-K filing: Processa Pharmaceuticals, Inc. closed a registered direct offering on February 14, 2023, selling 7,812,544 shares of common stock at $0.80 per share to accredited investors, resulting in gross proceeds of approximately $6.25 million and net proceeds of approximately $5.7 million after deducting fees and expenses. ($0.0M proceeds)

10-Q filing | 16.2M shares outstanding

10-Q filing | 15.9M shares outstanding

10-Q filing | 15.8M shares outstanding

10-K filing | 15.8M shares outstanding

8-K filing: Processa Pharmaceuticals, Inc. entered into a purchase agreement with Lincoln Park Capital Fund, LLC, for the sale of up to $15.0 million of shares of the Company's common stock, and issued 123,609 shares to Lincoln Park as a commitment fee.

10-Q filing | 15.7M shares outstanding

10-Q filing | 15.6M shares outstanding

10-Q filing | 14.2M shares outstanding

S-3 filing: The filing is an S-3 registration statement for the resale of 1,321,132 shares of common stock by selling stockholders, which were previously issued pursuant to a Securities Purchase Agreement dated February 15, 2021.

10-K filing | 5.5M shares outstanding

8-K filing: Processa Pharmaceuticals, Inc. entered into a securities purchase agreement for a private placement, selling 1,321,132 shares of common stock at $7.75 per share for gross proceeds of $10,238,773. ($10.24M proceeds)

10-Q filing | 5.5M shares outstanding

8-K filing: Processa Pharmaceuticals, Inc. closed a public offering of 4,800,000 shares of common stock at $4.00 per share, resulting in net proceeds of approximately $17.0 million and a total of 13,603,925 shares outstanding after the offering. ($19.2M proceeds)

S-1/A filing: Processa Pharmaceuticals, Inc. is offering 3,200,000 shares of common stock at an assumed price of $5.00 per share to conduct clinical trials and for working capital and other general corporate purposes.

S-1/A filing: This S-1/A filing relates to a proposed offering of common stock with the intention to use the net proceeds from this offering over the next 18-24 months to conduct clinical trials and for working capital and other general corporate purposes.

8-K filing: Processa Pharmaceuticals, Inc. entered into a License Agreement with Elion Oncology, Inc. to acquire an exclusive license to develop, manufacture and commercialize PCS6422 globally, contingent on an equity offering of at least $15 million and a Nasdaq up-listing, which includes issuing Elion 500,000 shares of common stock and additional milestone payments potentially in shares.

10-Q filing | 5.5M shares outstanding

S-1/A filing: Processa Pharmaceuticals, Inc. is offering 2,500,000 shares of common stock at an assumed price of $8.00 per share, with the intention to use the net proceeds primarily to fund continued development of and future clinical trials of their lead product candidate PCS499, to fund continued research and development of PCS11T and PCS100, and for working capital and other general corporate activities.

10-Q filing | 5.5M shares outstanding

10-K filing | 5.5M shares outstanding